About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis

IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis

NCT02241512·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Texas Southwestern Medical Center

Age

0–18

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Age\<=18 years
Undergoing ERCP (defined as cannulation of the major or minor papilla) for any indication

You may not be if

Age\>18
Pancreatitis within the 72 hours preceding ERCP
Allergy or hypersensitivity to Aspirin or NSAID medications
Pregnancy or breastfeeding mother
Cr \>1.4
Gastrointestinal hemorrhage in preceding 72 hours
Heart disease reliant upon a patient ductus arteriosis
History of sickle cell disease

The record

StatusTerminated

PhasePhase 2

Taking part69

StartedSep 2014

UpdatedFeb 18, 2020

Conditions

Post-ERCP Acute Pancreatitis

Where1

Children's Medical Center of Dallas
Dallas, Texas, United States